ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
June 15th, 2022, ProBio announced the license of ProteoNic BV's premium 2G UNic™ technology for boosting therapeutic protein production. ProteoNic BV is a leading provider of premium vector technology and services for efficient production of biologics.
Under the agreement, ProBio gains access to ProteoNic technology for the development of high-yielding cell lines for its clients. As a result, ProBio clients will profit from significantly reduced cost of goods for their products as well as increased product development efficiency and capacity.
ProteoNic's premium protein expression technology 2G UNic™ improves production levels across a range of mammalian host cells selection systems and protein targets. This is achieved via the combined effect of novel genetic elements, which together exert a positive effect on recombinant protein production levels. The technology increases production levels of complex proteins which are difficult to produce, including bi-specifics and fusion proteins as well as levels of products already in the multiple g/L range. Additionally, 2G UNic™ can be used to boost the performance of other expression enhancing technologies.
Frank Pieper, CEO of ProteoNic commented: "We are pleased that we can contribute to achieving the improvement in protein titer for ProBio and its clients. In this arrangement, ProBio will play an active role in the global distribution of our premium technology to product developers."
Dr.Brian Min, CEO of ProBio commented: "ProBio is continuously developing and optimizing the cell line technology to improve the titer of challenging molecules, like proteins and bi-specifics. This agreement illustrates ProBio's commitment to offering our customers the effective and cutting-edge tools in cell line development of biologics, lowering the R&D and manufacturing cost, and building a healthier future."
About ProteoNic BV
ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership arrangements. For more information, see www.proteonic.nl.
